Polycythemia vera (D45) ICD-10-CM
The D45 code range covers polycythemia vera with 1 ICD-10-CM diagnosis codes. 1 of them are billable and valid for claim submission in fiscal year 2027, and the category headers group them but cannot themselves be billed.
Type 1 Excludes
A type 1 excludes note is a pure excludes note. It means "NOT CODED HERE!" An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
Codes in the D45 Range 1 codes · 1 billable
- D45 Polycythemia vera
Clinical Terms in This Code Range
Definitions from the National Library of Medicine for conditions coded in the D45 range.
Polycythemia Vera
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
About the D45 Code Range
Polycythemia vera is a bone marrow disorder in which blood-forming cells multiply abnormally, increasing red blood cell mass and total blood volume.
The neoplasms chapter places D45 in a group with neoplasms of uncertain behavior and myelodysplastic syndromes.
Questions About This Page
How many billable codes are in the D45 range?
Of the 1 codes in this range, 1 are billable and valid for claim submission from October 1, 2026 through September 30, 2027. Category header codes group them but cannot be reported on claims.
What does the D45 range classify?
The range classifies polycythemia vera. Each code links to its own reference page with billing status, MS-DRG grouping, coding notes, and clinical information.
Related References
Source: CMS FY 2027 ICD-10-CM Tabular List and order file, effective October 1, 2026 through September 30, 2027.
